You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress
|
|---|---|
| Published in |
BMC Cancer, May 2016
|
| DOI | 10.1186/s12885-016-2354-6 |
| Pubmed ID | |
| Authors |
Hyun-Ah Kim, Sei Hyun Ahn, Seok Jin Nam, Seho Park, Jungsil Ro, Seock-Ah Im, Yong Sik Jung, Jung Han Yoon, Min Hee Hur, Yoon Ji Choi, Soo-Jung Lee, Joon Jeong, Se-Heon Cho, Sung Yong Kim, Min Hyuk Lee, Lee Su Kim, Byung-In Moon, Tae Hyun Kim, Chanheun Park, Sei Joong Kim, Sung Hoo Jung, Heungkyu Park, Geum Hee Gwak, Sun Hee Kang, Jong Gin Kim, Jeryong Kim, Su Yun Choi, Cheol-Wan Lim, Doyil Kim, Youngbum Yoo, Young-Jin Song, Yoon-Jung Kang, Sang Seol Jung, Hyuk Jai Shin, Kwan Ju Lee, Se-Hwan Han, Eun Sook Lee, Wonshik Han, Hee-Jung Kim, Woo Chul Noh |
| Abstract |
Ovarian function suppression (OFS) has been shown to be effective as adjuvant endocrine therapy in premenopausal women with hormone receptor-positive breast cancer. However, it is currently unclear if addition of OFS to standard tamoxifen therapy after completion of adjuvant chemotherapy results in a survival benefit. In 2008, the Korean Breast Cancer Society Study Group initiated the ASTRRA randomized phase III trial to evaluate the efficacy of OFS in addition to standard tamoxifen treatment in hormone receptor-positive breast cancer patients who remain or regain premenopausal status after chemotherapy. Premenopausal women with estrogen receptor-positive breast cancer treated with definitive surgery were enrolled after completion of neoadjuvant or adjuvant chemotherapy. Ovarian function was assessed at the time of enrollment and every 6 months for 2 years by follicular-stimulating hormone levels and bleeding history. If ovarian function was confirmed as premenopausal status, the patient was randomized to receive 2 years of goserelin plus 5 years of tamoxifen treatment or 5 years of tamoxifen alone. The primary end point will be the comparison of the 5-year disease-free survival rates between the OFS and tamoxifen alone groups. Patient recruitment was finished on March 2014 with the inclusion of a total of 1483 patients. The interim analysis will be performed at the time of the observation of the 187th event. This study will provide evidence of the benefit of OFS plus tamoxifen compared with tamoxifen only in premenopausal patients with estrogen receptor-positive breast cancer treated with chemotherapy. ClinicalTrials.gov Identifier NCT00912548 . Registered May 31 2009. Korean Breast Cancer Society Study Group Register KBCSG005 . Registered October 26 2009. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 2% |
| France | 1 | 2% |
| Unknown | 64 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 14% |
| Student > Master | 8 | 12% |
| Student > Bachelor | 7 | 11% |
| Student > Doctoral Student | 5 | 8% |
| Student > Postgraduate | 5 | 8% |
| Other | 15 | 23% |
| Unknown | 17 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 38% |
| Nursing and Health Professions | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Sports and Recreations | 2 | 3% |
| Other | 9 | 14% |
| Unknown | 18 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2018.
All research outputs
#13,235,371
of 22,870,727 outputs
Outputs from BMC Cancer
#2,841
of 8,322 outputs
Outputs of similar age
#169,221
of 334,143 outputs
Outputs of similar age from BMC Cancer
#26
of 94 outputs
Altmetric has tracked 22,870,727 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,322 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,143 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.